{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:05:49Z","timestamp":1791547549559,"version":"4.3.4"},"reference-count":53,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Survodutide, a novel glucagon receptor and glucagon\u2010like peptide\u20101 (GLP\u20101) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report the baseline characteristics of participants in the SYNCHRONIZE\u20101 trial in adults with obesity without T2D (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      : NCT06066515).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Participants aged \u226518\u2009years with BMI \u226530 or \u226527\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with \u22651 obesity complication without T2D were randomized 1:1:1 to double\u2010blind, once\u2010weekly, subcutaneous injections of survodutide (up\u2010titrated to 3.6 or 6.0\u2009mg) or placebo for 76\u2009weeks. The primary endpoints are percent body weight change and achievement of body weight reduction \u22655% from baseline to Week 76. Efficacy and safety analyses will include all randomized and treated participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, participants (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009725 from 14 countries) had a mean age of 47.1\u2009years, BMI 37.9\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and waist circumference 115.2\u2009cm. Most participants (59.4%) were female; 47.3% were from North America, 21.0% from Europe, and 20.0% from East Asia. Obesity complications included hypertension (40.0%), dyslipidaemia (33.7%), and prediabetes (30.2%). Mean haemoglobin A1c was 5.5%, estimated glomerular filtration rate 93.0\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      , systolic\/diastolic blood pressure 127.0\/82.7\u2009mmHg, and low\u2010density lipoprotein cholesterol 116.4\u2009mg\/dL; 21.8% were taking lipid\u2010lowering drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SYNCHRONIZE\u20101 will determine the efficacy, safety, and tolerability of survodutide, a glucagon receptor\/GLP\u20101 receptor dual agonist, for weight loss in a representative cohort of people with obesity without T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70196","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:45:26Z","timestamp":1762303526000},"page":"337-346","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double\u2010blind, placebo\u2010controlled, phase 3 trial (\n                    <scp>SYNCHRONIZE<\/scp>\n                    \u2122\u20101)"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"Carel W.","family":"le Roux","sequence":"first","affiliation":[{"name":"University College Dublin School of Medicine  Dublin Ireland"},{"name":"Ulster University  Coleraine UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-1530","authenticated-orcid":false,"given":"Sean","family":"Wharton","sequence":"additional","affiliation":[{"name":"McMaster University  Hamilton Ontario Canada"},{"name":"University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Winters Center for Heart Failure Research, Cardiovascular Research Institute Baylor College of Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-0710","authenticated-orcid":false,"given":"Elke","family":"Platz","sequence":"additional","affiliation":[{"name":"Cardiovascular Division Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-9042","authenticated-orcid":false,"given":"Gabriele","family":"Bleckert","sequence":"additional","affiliation":[{"name":"Staburo GmbH, on behalf of Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Biberach an der Ri\u00df Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4849-0363","authenticated-orcid":false,"given":"Samina","family":"Ajaz Hussain","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-0746","authenticated-orcid":false,"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"},{"name":"First Department of Medicine, Faculty of Medicine Mannheim University of Heidelberg  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Startseva","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel M.","family":"Kloer","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim am Rhein Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6301-2696","authenticated-orcid":false,"given":"Lee M.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Medicine Geisel School of Medicine at Dartmouth  Hanover New Hampshire USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12551"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2021.100004"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003095\u20103"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(24)00316\u20104"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15478"},{"key":"e_1_2_10_7_1","volume-title":"World Obesity Atlas 2023","author":"World Obesity Federation","year":"2023"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)00355\u20101"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)02750\u20102"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.004"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000442721"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S008"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102214"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00025.2016"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1113\/JP287407"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101633"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(23)00356\u2010X"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010023\u201006053\u20109"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14948"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24184"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.09.004"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_2_10_30_1","unstructured":"Guidance for industry: developing products for weight management (February 2007). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)."},{"key":"e_1_2_10_31_1","unstructured":"Obesity and overweight: developing drugs and biological products for weight reduction\u2014guidance for industry (January 2025). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/obesity-and-overweight-developing-drugs-and-biological-products-weight-reduction"},{"key":"e_1_2_10_32_1","unstructured":"Guideline on clinical evaluation of medicinal products used in weight management (1 January 2017). European Medicines Agency an agency of the European Union.https:\/\/www.ema.europa.eu\/en\/clinical-evaluation-medicinal-products-used-weight-control-scientific-guideline"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24299"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh\u20102024\u2010017177"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.140"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2015.04.005"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40615\u2010022\u201001487\u20100"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(24)00098\u20106"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920\u2010025\u201001601\u2010z"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24300"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.06.001"},{"issue":"1","key":"e_1_2_10_42_1","first-page":"S361","article-title":"Body weight reduction with tirzepatide by sex: a subgroup analysis of the SURMOUNT clinical trials","volume":"67","author":"Garc\u00eda\u2010P\u00e9rez L\u2010E","year":"2024","journal-title":"Diabetologia"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae165"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030454"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020199"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411528"},{"issue":"3","key":"e_1_2_10_47_1","first-page":"245","article-title":"Effect of body mass index on all\u2010cause mortality and incidence of cardiovascular diseases\u2014report for meta\u2010analysis of prospective studies open optimal cut\u2010off points of body mass index in Chinese adults","volume":"15","author":"Zhou BF","year":"2002","journal-title":"Biomed Environ Sci"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2024.171219"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15693"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16660"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.016334"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.11153"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2021.2002616"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:57:00Z","timestamp":1772989020000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/dom.70196"],"URL":"https:\/\/doi.org\/10.1111\/dom.70196","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70196\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70196\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70196\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70196\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70196\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70196\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70196\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"2025-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}